Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

被引:1224
作者
Cho, HS
Mason, K
Ramyar, KX
Stanley, AM
Gabelli, SB
Denney, DW
Leahy, DJ
机构
[1] Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA
[3] Genitope Corp, Redwood City, CA 94063 USA
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
D O I
10.1038/nature01392
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4 (ERBB4)(1). ErbB receptors are essential mediators of cell proliferation and differentiation in the developing embryo and in adult tissues(2), and their inappropriate activation is associated with the development and severity of many cancers(3). Overexpression of HER2 is found in 20-30% of human breast cancers, and correlates with more aggressive tumours and a poorer prognosis(4). Anticancer therapies targeting ErbB receptors have shown promise, and a monoclonal antibody against HER2, Herceptin (also known as trastuzumab), is currently in use as a treatment for breast cancer(5). Here we report crystal structures of the entire extracellular regions of rat HER2 at 2.4 Angstrom and human HER2 complexed with the Herceptin antigen-binding fragment (Fab) at 2.5 Angstrom. These structures reveal a fixed conformation for HER2 that resembles a ligand-activated state, and show HER2 poised to interact with other ErbB receptors in the absence of direct ligand binding. Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies.
引用
收藏
页码:756 / 760
页数:6
相关论文
共 31 条
[21]   AMORE - AN AUTOMATED PACKAGE FOR MOLECULAR REPLACEMENT [J].
NAVAZA, J .
ACTA CRYSTALLOGRAPHICA SECTION A, 1994, 50 :157-163
[22]   Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains [J].
Ogiso, H ;
Ishitani, R ;
Nureki, O ;
Fukai, S ;
Yamanaka, M ;
Kim, JH ;
Saito, K ;
Sakamoto, A ;
Inoue, M ;
Shirouzu, M ;
Yokoyama, S .
CELL, 2002, 110 (06) :775-787
[23]   The ErbB signaling network: receptor heterodimerization in development and cancer [J].
Olayioye, MA ;
Neve, RM ;
Lane, HA ;
Hynes, NE .
EMBO JOURNAL, 2000, 19 (13) :3159-3167
[24]   Cell Signaling by Receptor Tyrosine Kinases [J].
Lemmon, Mark A. ;
Schlessinger, Joseph .
CELL, 2010, 141 (07) :1117-1134
[25]   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].
Slamon, DJ ;
Leyland-Jones, B ;
Shak, S ;
Fuchs, H ;
Paton, V ;
Bajamonde, A ;
Fleming, T ;
Eiermann, W ;
Wolter, J ;
Pegram, M ;
Baselga, J ;
Norton, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792
[26]   HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].
SLAMON, DJ ;
CLARK, GM ;
WONG, SG ;
LEVIN, WJ ;
ULLRICH, A ;
MCGUIRE, WL .
SCIENCE, 1987, 235 (4785) :177-182
[27]  
Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60
[28]  
TANG CK, 1998, HORMONES SIGNALING, V1, P113
[29]   MOLREP: an automated program for molecular replacement [J].
Vagin, A ;
Teplyakov, A .
JOURNAL OF APPLIED CRYSTALLOGRAPHY, 1997, 30 :1022-1025
[30]   Use of TLS parameters to model anisotropic displacements in macromolecular refinement [J].
Winn, MD ;
Isupov, MN ;
Murshudov, GN .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2001, 57 :122-133